These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 15357651)

  • 41. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.
    Poynard T; Marcellin P; Bissery A; Myers RP; Moussalli J; Degos F; Dhumeaux D; Riachi G; Bronowicki JP; Brissot P; Buffet C; Serfaty L; Naveau S; Sogni P; Beaugrand M; Gayno S; Larrey D; Samuel D; Eugene C; Pol S; Bedossa P; Daurat V; Chaumet-Riffaud P;
    J Viral Hepat; 2003 May; 10(3):197-204. PubMed ID: 12753338
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.
    Kamal SM; El Tawil AA; Nakano T; He Q; Rasenack J; Hakam SA; Saleh WA; Ismail A; Aziz AA; Madwar MA
    Gut; 2005 Jun; 54(6):858-66. PubMed ID: 15888797
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of early viral kinetics on pegylated interferon alpha 2b plus ribavirin therapy in Japanese patients with genotype 2 chronic hepatitis C.
    Nomura H; Miyagi Y; Tanimoto H; Ishibashi H
    J Viral Hepat; 2009 May; 16(5):346-51. PubMed ID: 19222743
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy.
    Takahashi M; Saito H; Higashimoto M; Atsukawa K; Ishii H
    J Clin Microbiol; 2005 Jan; 43(1):186-91. PubMed ID: 15634970
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy.
    François C; Descamps V; Brochot E; Bernard I; Canva V; Mathurin P; Castelain S; Duverlie G
    J Med Virol; 2010 Oct; 82(10):1640-6. PubMed ID: 20827759
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prolonged negative HCV-RNA status led to a good outcome in chronic hepatitis C patients with genotype 1b and super-high viral load.
    Kohno H; Aimitsu S; Kitamoto M; Aisaka Y; Kawakami H; Chayama K
    Intervirology; 2006; 49(6):362-9. PubMed ID: 16926549
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
    J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.
    Sjogren MH; Sjogren R; Holtzmuller K; Winston B; Butterfield B; Drake S; Watts A; Howard R; Smith M
    Dig Dis Sci; 2005 Apr; 50(4):727-32. PubMed ID: 15844709
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Blood serum glutathione alpha s-transferase (alpha GST) activity during antiviral therapy in patients with chronic hepatitis C.
    Mazur W; Gonciarz M; Kajdy M; Mazurek U; Jurzak M; Wilczok T; Gonciarz Z
    Med Sci Monit; 2003 Aug; 9 Suppl 3():44-8. PubMed ID: 15156612
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C.
    Murata K; Yamamoto N; Kawakita T; Saito Y; Yamanaka Y; Sugimoto K; Shiraki K; Nakano T; Tameda Y
    Hepatogastroenterology; 2005; 52(62):547-51. PubMed ID: 15816475
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatic interferon receptor mRNA expression: clinical relevance and its relationship with effectiveness of interferon plus ribavirin therapy in patients with genotype 1b hepatitis C virus infection.
    Lee CM; Kee KM; Hung CH; Eng HL; Chang CH; Huang CM; Wang JH; Hu TH; Lu SN; Changchien CS; Chen WJ
    Antivir Ther; 2006; 11(1):17-23. PubMed ID: 16518956
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
    Lunel F; Veillon P; Fouchard-Hubert I; Loustaud-Ratti V; Abergel A; Silvain C; Rifflet H; Blanchi A; Causse X; Bacq Y; Payan C;
    J Hepatol; 2003 Nov; 39(5):826-33. PubMed ID: 14568267
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High sustained virological response in chronic hepatitis C by combining induction and prolonged maintenance therapy.
    Vrolijk JM; Bekkering FC; Brouwer JT; Hansen BE; Schalm SW
    J Viral Hepat; 2003 May; 10(3):205-9. PubMed ID: 12753339
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy.
    Mori N; Imamura M; Kawakami Y; Saneto H; Kawaoka T; Takaki S; Aikata H; Takahashi S; Chayama K;
    J Med Virol; 2009 Apr; 81(4):640-9. PubMed ID: 19235866
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-viral actions and viral dynamics in the early phase of three different regimens of interferon treatment for chronic hepatitis C: differences between the twice-daily administration of interferon-beta treatment and the combination therapy with interferon-alpha plus ribavirin.
    Nakajima H; Shimomura H; Iwasaki Y; Ikeda F; Umeoka F; Chengyu P; Taniguchi H; Ohnishi Y; Takagi SJ; Fujioka S; Shiratori Y
    Acta Med Okayama; 2003 Oct; 57(5):217-25. PubMed ID: 14679399
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of hepatitis C virus infection in patients of northern India.
    Hazari S; Panda SK; Gupta SD; Batra Y; Singh R; Acharya SK
    J Gastroenterol Hepatol; 2004 Sep; 19(9):1058-65. PubMed ID: 15304125
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.
    Reichard O; Norkrans G; Frydén A; Braconier JH; Sönnerborg A; Weiland O
    Lancet; 1998 Jan; 351(9096):83-7. PubMed ID: 9439491
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C.
    Fattovich G; Zagni I; Fornaciari G; Minola E; Fabris P; Boccia S; Giusti M; Abbati G; Felder M; Rovere P; Redaelli A; Tonon A; Montanari R; Paternoster C; Distasi M; Castagnetti E; Tositti G; Rizzo C; Suppressa S; Pantalena M; Lomonaco L; Scattolini C; Tagger A
    J Viral Hepat; 2003 Mar; 10(2):111-7. PubMed ID: 12614467
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study.
    da Silva LC; Bassit L; Ono-Nita SK; Pinho JR; Nishiya A; Madruga CL; Carrilho FJ
    J Gastroenterol; 2002; 37(9):732-6. PubMed ID: 12375147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.